Halozyme Therapeutics, Inc. (HALO) stock
HALONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 13/3037% above fair value
$95.80−0.17 (-0.18%)
Close on Nov 18, 2026Market cap $10.87BP/E 28.3Yield –
Halozyme Therapeutics enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Halozyme Therapeutics's enterprise value was $13.58B on Nov 11, 2026, against $9.48B a year earlier. Over the last 5 years it ranged from $4.15B to $16.91B, with a median of $7.74B.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $13.58B | +50.9% |
| 2025 | Dec 31, 2025 | $9.00B | +21.1% |
| 2024 | Dec 31, 2024 | $7.43B | +21.7% |
| 2023 | Dec 29, 2023 | $6.11B | -31.6% |
| 2022 | Dec 30, 2022 | $8.93B | +80.8% |
| 2021 | Dec 31, 2021 | $4.94B | -9.1% |
| 2020 | Dec 31, 2020 | $5.43B | +109.7% |
| 2019 | Dec 31, 2019 | $2.59B | +20.7% |
| 2018 | Dec 31, 2018 | $2.15B | -22.7% |
| 2017 | Dec 29, 2017 | $2.78B | +126.0% |
| 2016 | Dec 30, 2016 | $1.23B | -43.0% |
| 2015 | Dec 31, 2015 | $2.16B | +83.7% |
| 2014 | Dec 31, 2014 | $1.18B | -30.8% |
| 2013 | Dec 31, 2013 | $1.70B | +153.9% |
| 2012 | Dec 31, 2012 | $668.55M | -27.3% |
| 2011 | Dec 30, 2011 | $919.36M | – |
See a number that looks wrong?